U.S. Markets closed

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Zacks Equity Research
Is (MCS) Outperforming Other Consumer Discretionary Stocks This Year?

In the latest trading session, Gilead Sciences (GILD) closed at $70.90, marking a +1.66% move from the previous day. This change outpaced the S&P 500's 0.66% loss on the day. At the same time, the Dow lost 0.99%, and the tech-heavy Nasdaq lost 1.63%.

Coming into today, shares of the HIV and hepatitis C drugmaker had lost 8.93% in the past month. In that same time, the Medical sector lost 9.8%, while the S&P 500 lost 8.1%.

GILD will be looking to display strength as it nears its next earnings release, which is expected to be February 5, 2019. The company is expected to report EPS of $1.65, down 7.3% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.48 billion, down 7.83% from the year-ago period.

GILD's full-year Zacks Consensus Estimates are calling for earnings of $6.63 per share and revenue of $21.79 billion. These results would represent year-over-year changes of -25% and -16.52%, respectively.

Any recent changes to analyst estimates for GILD should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.61% higher. GILD currently has a Zacks Rank of #2 (Buy).

Investors should also note GILD's current valuation metrics, including its Forward P/E ratio of 10.51. This represents a discount compared to its industry's average Forward P/E of 26.41.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 85, which puts it in the top 33% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.